Ensign Peak Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
Other funds holding RARE
Ensign Peak Advisors's RARE Position: Q3 2026 in Review
Ensign Peak Advisors reduced its Ultragenyx Pharmaceutical (RARE) stake by 11% in Q3 2026, selling an estimated $799K and leaving 257,525 shares worth $3.87M. The position accounts for 0.01% of the portfolio, ranked #630.
Ensign Peak Advisors first reported a position in RARE in Q4 2021 and has held it in 20 quarters since. The position peaked at $9.7M in Q2 2026. 268 funds tracked by Wall St. Rank hold RARE as of Q3 2026.
- Ensign Peak Advisors held 257,525 shares of Ultragenyx Pharmaceutical worth $3.87M as of Q3 2026.
- Ensign Peak Advisors sold 33,293 Ultragenyx Pharmaceutical shares in Q3 2026, an estimated $799K.
- Ultragenyx Pharmaceutical made up 0.01% of Ensign Peak Advisors's portfolio in Q3 2026, its #630 holding.
- Ensign Peak Advisors first reported a position in Ultragenyx Pharmaceutical in Q4 2021 and has held it in 20 quarters since.
- Ensign Peak Advisors's Ultragenyx Pharmaceutical position peaked at $9.7M in Q2 2026.
- 268 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2026.
Based on Ensign Peak Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.